当前位置:首页 > 报告详情

FRE_prsn_JPM SFO.pdf

上传人: c** 编号:603966 2025-02-03 15页 1.59MB

1、#FutureFreseniusCommitted to LifeJ.P.Morgan Healthcare Conference,San Francisco,14 January 2025Safe Harbor StatementThis presentation contains forward-looking statements that are subject to various risks and uncertainties.Future results could differ materially from those described in these forward-l

2、ooking statements due to certain factors,e.g.changes in business,economic and competitive conditions,regulatory reforms,results of clinical trials,foreign exchange rate fluctuations,uncertainties in litigation or investigative proceedings,the availability of financing and unforeseen impacts of inter

3、national conflicts.Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.J.P.Morgan Healthcare Conference Fresenius SE&Co.KGaA Investor Relations21UN Ageing&Health(2021)|2Financing Global Health,Institute for Health Metrics and Evalua

4、tion(2024)|3 Centers for Medicare and Medicaid Services(2024)|4Global Burden of Disease,Institute for Health Metrics and Evaluation(2022)|5WHO Health Workforce(2023)Demand for health workforce10mgap of health and care workers globally by 20305Ageing global population+40%to 1.4bn people 60 years worl

5、dwide by 20301Increasing healthcare spendHealth expenditures rise to 10%of global GDP by 20302with U.S.healthcare spend alone nearing$5tn in 20233Higher prevalence of chronic diseases84%of 67m deaths globally in 2030 due to chronic diseases43J.P.Morgan Healthcare Conference Fresenius SE&Co.KGaA Inve

6、stor RelationsStrong needs underpinning secular sector growthA stronger,simpler and focused healthcare companyJ.P.Morgan Healthcare Conference Fresenius SE&Co.KGaA Investor RelationsFresenius KabiFresenius HeliosPharmaBiopharmaNutritionMedTechCare provision platformMedTech platform(Bio)Pharma platfo

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
Fresenius是一家致力于医疗健康的公司,在2025年1月14日的J.P. Morgan Healthcare Conference上,分享了其对未来医疗领域的展望和承诺。公司预计到2030年全球将有10亿健康和护理工作者的缺口,同时全球60岁以上的人口将增加到14亿。随着慢性疾病的发病率上升,医疗支出预计将占到全球GDP的10%以上。Fresenius在多个领域处于领先地位,包括全球IV药物市场第一,全球Parenteral Nutrition市场第二。公司拥有广泛的医疗产品和服务,包括IV药物和营养、生物制药、透析和细胞疗法等。Fresenius还强调了其在医疗技术领域的优势,如IV泵和输液系统,并在全球范围内拥有超过100万台的医疗泵。此外,公司还拥有30多项关于注射和肠内营养的研究,以及超过10个生物仿制药资产。Fresenius致力于通过创新和高效运营,实现财务和业绩的增长,预计到2023年其EBIT利润率将达10-12%,有机收入增长率将达到4-6%。
Fresenius如何应对全球医疗工作者的短缺? 未来 Fresenius 将如何扩大其在哪方面的市场份额? Fresenius 计划如何实现财务目标并提高股东回报?
客服
商务合作
小程序
服务号
折叠